fecal diagnost market afraid step
messag custom check suggest zoeti and/or could launch
fecal analyz think big enough market around
add above-market growth provid fecal analyz vet clinic move
mostli manual approach autom in-clin option plan launch fecal
analyz beta think investor get excit
whole diagnost group buy rate check could
also posit neutral-r
call believ potenti in-clin fecal test market could built
next coupl year could bullish diagnost compani zoeti
assum former two launch analyz think diagnost
market best posit anim health given higher growth rate limit
competit rivalri includ privat player specif antech four largest
player veterinari diagnost insid outsid lab account revenu
custom check time regular check veterinarian corpor
practic group discov compani conduct market research check
fecal analyz spoke said conduct
activ lead us believ either zoeti potenti like
plan launch insid lab instrument fecal analysi veterinari medicin
compani showcas new product vmx wvc confer jan feb
respect base prior new product cycles/announc would put product
launch time around bit plan launch
bullish fecal market us need better diagnost fecal analysi
think refer lab offer includ antigen test improv
prior method veterinarian clinic microscop train lab
technician central lab though fecal antigen test improv diagnosi gap
remain veterinarian want immedi result autom test particularli
one could improv sensit without sacrif specif would see adopt
excess adopt seen urin sediment market view recal veterinarian
run fecal test urin test accord research
diagnost compani charg higher price vs essenti free incumb
view incumb technolog detect intestin parasit infect
microscop slide veterinari offic alreadi microscop slide
cost penni although incumb method cost penni alreadi see move
test done hospit lab outsid refer lab veterinarian will
pay per custom check avoid in-clin handl
found veterinarian trust train clinician refer lab look
hundr sampl day staff
pay even outsid lab benefit avail clinic view
think in-clin option addit offer immedi result could result much higher
complianc typic refer lab requir full cup sampl either entail
dog go command pet parent come back clinic sampl
insid lab analyz offer accuraci conveni lesser handl
page analyst certif import disclosur
outsid test plu faster turnaround time higher complianc insid lab test
think veterinarian pay premium word vet alreadi will go
essenti free better result think veterinarian would spend
sampl addit improv in-hous test
market size peg market opportun fecal test around capc
estim fecal test run per year north america estim use
averag rate opportun estim european market
half size longer term believ vet run
fecal test charg higher price access better method note
estim market analyst day august heska
assum price higher although estim lower compani also
done dilig well word wrong probabl
page analyst certif import disclosur
custom check suggest either zoeti perhap could launch
fecal analyz think fecal market big enough around
contribut above-market growth provid diagnost zoeti
still track launch fecal analyz say unit beta
net-net posit potenti revenu impact industri move
mostli manual approach autom in-clin option posit benefit
whole group believ stand benefit given smaller revenu base
reiter buy rate zoeti also bullish
previous though need bit better risk/return get construct
improv microscop method opportun us today estim
half veterinari fecal test done clinic microscop although method
inexpens cost veterinarian time lower sensit brought human error
technolog could improv upon addit note mani time even
parasit present sampl evid observ
use microscop time veterinarian use microscop look egg
process less handl fece
sensit test
time result
employe time spend time test via microscop
figur shown altern fecal analysi method allow identif
whipworm-specif antigen significantli earlier possibl incumb method
custom check conduct regular quarterli interview veterinarian
corpor practic group told market research effort conduct
new fecal analyz spoke told us run recent market
page analyst certif import disclosur
research effort surpris zoeti estim
market share respect veterinari diagnost alreadi urin analyz
market like firm launch fecal analyz opinion recal insid
lab diagnost three largest player account roughli total revenu
zoeti cant say sure think like zoeti
conduct check origin go use snap test cancel think
would take time pivot new approach said almost alway first
market alreadi refer lab test shown interest market regardless
think three compani eventu product given market size
time anim health compani showcas new product vmx wvc
confer two largest confer januari februari respect common
educ effort begin less year product launch compani
typic present instrument prototype/form factor show veterinarian see prior
product launch think product go market research effort right
would go show would put product launch timelin
approxim new product particularli first market product would see
meaning revenu impact first quarter launch wouldnt like see
posit impact suspect market wont becom materi anyon
one two biggest compani zoeti invest educ effort
word think launch alon would move market
instrument might work/look weve spoken abaxi zoeti
topic quit time believ compani could approach market
use equip imag recognit softwar read parasit microscop
point-of-car poc molecular diagnost platform combin size wise
platform would fit lab bench somewhat mobil veterinarian call
zoetis/abaxi vetscan sa urin sediment analyz bulki
weigh almost lb believ repres big analyz could go
particularli veterinarian insid lab lack excess counter space
analyst day mention use sedivu type approach
instrument use facial recognition-lik softwar look imag
parasit egg microscop sensit would dictat softwar
biolog parasit believ howev approach
assum hasnt made chang sinc publicli announc platform would result
better sensit human use microscop wed guess would
care look specif limit fals neg would limit sensit
hard time believ would sensit idexx fecal antigen
refer lab test doesnt long improv upon manual process
high specif sensit higher human think sell
said believ pure optic approach doesnt solv
issu detect egg present given sampl use
antigen-bas diagnost approach refer lab back human
microscop attempt snap-bas approach small cartridg
pregnanc test form factor cancel believ origin product
page analyst certif import disclosur
difficulti specificity/sensit trade origin educ market
in-clin fecal test superior think enter market particularli
zoeti enter wouldnt surpris approach market
pcr-base test sort combin optic molecular method
said impli current refer lab method see improv
sensit key opportun
zoeti abaxi prior zoeti acquisit spoke us skeptic heska
approach given product cycl longer coupl year zoeti
attack fecal market next year effort would like begun abaxi
team point realli limit visibl possibl fecal
offer zoeti
slide price penni diagnost compani charg veterinari
diagnost compani like need train market chang test paradigm
dont believ compani charg right away idexx assumpt
recal mani veterinarian particularli small practic use method test
microscop cost penni veterinarian weve spoke larger hospit told us
cost roughli per test send antech part mar though weve
heard price high
assumpt idexx assumpt seem bit high
rel vet weve spoken sell exponenti fecal test
number custom weve spoke agre compani diagnost
compani abil charg meaning premium even price vet
pay send test
addit benefit note previous vs slide method also believ insid lab
analyz benefit versu refer lab insid lab test would higher complianc
due lower sampl requir outsid lab test requir full jar sampl usual
page analyst certif import disclosur
reluct pet owner bluntli speak carri jar dog poop veterinari
clinic higher complianc assum accuraci equal would lead catch
diseas ultim practic catch twice number infect see slide
think diagnost compani could charg roughli twice price given increas veterinari
practic revenu coupl factor would drive test idexx fecal
antigen test studi almost sampl found twice amount infect compar
tradit microscop method
figur idexx fecal test result vs incumb microscope-bas method
understand market size estim total address market fecal
test insid lab outsid lab analyst day want highlight
use estim includ insid outsid lab us impli
in-clin opportun mind year prior analyst day
compani estim north american base estim fecal test
run practic refer lab averag price think north america
bit high rel estim nonetheless respect market estim feel
comfort compani data back note estim
insid clinic
page analyst certif import disclosur
figur idexx fecal test result vs incumb microscope-bas method
market estim use price per test least earli launch believ
capc estim test run us/canada correct would put north
american tam roughli gener rule anim health european market
size us market round given
europ would requir bigger invest address bring total
estim market note longer term believ veterinarian run
fecal test access better test method charg higher price
would repres potenti upsid market estim believ time
market could well billion dollar infrastructur requir realiz potenti
includ educ effort isnt yet place
could penetr look like think use in-clin urin sediment market
proxi launch might look like estim total urin sediment market
made almost exclus idexx sedivu revenu
first three year launch instal base went
end expect market share three-hors race would compar
chemistri market share zoeti respect
matur would impli increment revenu zoeti
year three assum chemistry-lik market share distribut
buy bullish follow research previous
skeptic abil penetr fecal diagnost market
signific amount custom educ requir switch veterinarian new class
product believ competit platform would help grow market meaning
could benefit windfal said maintain neutral rate dont
price target howev use sotp analysi arriv fair valu
page analyst certif import disclosur
valuat sotp sum-of-the-part analysi break three
differ busi first believ blood diagnost busi revenu
estim deserv valuat closer diagnost peer zoeti
neutral believ revenu multipl revenu
appropri slight discount zoeti trade averag
imag busi lower margin lower growth busi
revenu believ busi deserv revenu multipl final
ovp companion anim product categori revenu low
growth low margin busi put revenu multipl busi note
sale common multipl low- no-growth low margin diagnost busi
triniti biotech trib nc meridian bioscienc nc
page analyst certif import disclosur
new abroad strategi begin aggress strategi sell abroad
take time resourc product demand unknown could lead meaning
fecal/urin analyz product could game-chang success could catapult
expect neg growth yoy compani also
set guidanc street expect think final hit point
bad news
 could acquir asset would significantli move revenu
distributor risk part revenu result distributor partner
reput risk seen year inferior product hard
shake
 spend strategi although fulli think invest new product win strategi
quit new concept compani like see failur along
page analyst certif import disclosur
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst research associ receiv compens base upon variou factor includ qualiti research investor client
feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic heska corpor
inc zoeti inc next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori heska corpor
rate price target histori inc
creat bluematrix
creat bluematrix
page analyst certif import disclosur
